Preprint · CC-BY
via bioRxiv
Label free metabolic imaging to enhance the efficacy of Chimeric Antigen Receptor T cell therapy
Pham, D. L., Cappabianca, D., Forsberg, M., Weaver, C., Mueller, K. P., Tommasi, A., Vidugiriene, J., Lauer, A., Sylvester, K., Bugel, M., Capitini, C. M., Saha, K., Skala, M. C.
biorxiv · 2024
Abstract
Chimeric antigen receptor (CAR) T cell therapy for solid tumors remains challenging due to the complex manufacturing process and the immunosuppressive tumor microenvironment. The manufacturing condition directly impacts CAR T cell yield, phenotype, and metabolism, which correlate with in vivo potency and persistence. Optical metabolic imaging (OMI) is a non-invasive, label-free method to evaluate single cell metabolism based on autofluorescent metabolic coenzymes NAD(P)H and FAD. Using OMI, we identified the dominating impacts of media composition over the selection of antibody stimulation and/or cytokines on anti-GD2 CAR T cell metabolism, activation strength and kinetics, and phenotype. We demonstrated that OMI parameters were indicative of cell cycle stage and optimal gene transfer conditions for both viral transduction and electroporation-based CRISPR/Cas9. Notably, OMI accurately predicted oxidative metabolic phenotype of virus-free CRISPR-edited anti-GD2 CAR T cells that correlated to higher in vivo potency against neuroblastoma. Our data supports OMIs potential as a robust, sensitive analytical tool that enables dynamic and optimal manufacturing conditions for increased CAR T cell yield and metabolic fitness.
One sentence summaryAutofluorescence imaging informs manufacturing conditions that enhance yield and metabolic fitness of CAR T cells for neuroblastoma.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- bioRxiv
- DOI
- 10.1101/2024.02.20.581240
- Canonical
- link ↗
- Fetched
- 2026-10-11 MST
Cite this
APA
L., P.D., D., C., M., F., C., W., P., M.K., A., T., J., V., A., L., K., S., M., B., M., C.C., K., S., & C., S.M. (2024). Label free metabolic imaging to enhance the efficacy of Chimeric Antigen Receptor T cell therapy. <em>biorxiv</em>. https://doi.org/10.1101/2024.02.20.581240
Vancouver
L. PD, D. C, M. F, C. W, P. MK, A. T, et al. Label free metabolic imaging to enhance the efficacy of Chimeric Antigen Receptor T cell therapy. biorxiv. 2024. doi:10.1101/2024.02.20.581240.
BibTeX
@unpublished{pham2024Labelf,
title = {Label free metabolic imaging to enhance the efficacy of Chimeric Antigen Receptor T cell therapy},
author = {Pham, D. L. and Cappabianca, D. and Forsberg, M. and Weaver, C. and Mueller, K. P. and Tommasi, A. and Vidugiriene, J. and Lauer, A. and Sylvester, K. and Bugel, M. and Capitini, C. M. and Saha, K. and Skala, M. C.},
journal = {biorxiv},
year = {2024},
doi = {10.1101/2024.02.20.581240},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Nature Cancer 2025
Open access · CC-BY
Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure
Cell Reports 2021
Open access · CC-BY
Aging-dependent mitochondrial dysfunction mediated by ceramide signaling inhibits antitumor T cell response
Proceedings of the National Academy of Sciences 2025
Open access · CC-BY
Engineering chronological lifespan toward a robust yeast cell factory
Proceedings of the National Academy of Sciences of the United States of America 2025
Open access · OA
Engineering chronological lifespan toward a robust yeast cell factory.
Research (Washington, D.C.) 2026
Open access · OA
Chimeric Antigen Receptor T Cells as Living Therapeutics Targeting Senescence and Age-Related Diseases.
Journal of Pharmaceutical and Biomedical Analysis 2021
Citation only